Literature DB >> 34659650

Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.

Nawamin Sa-Nguanmoo1,2, Katawut Namdee3, Mattaka Khongkow3, Uracha Ruktanonchai3, YongXiang Zhao4, Xing-Jie Liang1,2.   

Abstract

Vaccination is the most effective way to prevent coronavirus disease 2019 (COVID-19). Vaccine development approaches consist of viral vector vaccines, DNA vaccine, RNA vaccine, live attenuated virus, and recombinant proteins, which elicit a specific immune response. The use of nanoparticles displaying antigen is one of the alternative approaches to conventional vaccines. This is due to the fact that nano-based vaccines are stable, able to target, form images, and offer an opportunity to enhance the immune responses. The diameters of ultrafine nanoparticles are in the range of 1-100 nm. The application of nanotechnology on vaccine design provides precise fabrication of nanomaterials with desirable properties and ability to eliminate undesirable features. To be successful, nanomaterials must be uptaken into the cell, especially into the target and able to modulate cellular functions at the subcellular levels. The advantages of nano-based vaccines are the ability to protect a cargo such as RNA, DNA, protein, or synthesis substance and have enhanced stability in a broad range of pH, ambient temperatures, and humidity for long-term storage. Moreover, nano-based vaccines can be engineered to overcome biological barriers such as nonspecific distribution in order to elicit functions in antigen presenting cells. In this review, we will summarize on the developing COVID-19 vaccine strategies and how the nanotechnology can enhance antigen presentation and strong immunogenicity using advanced technology in nanocarrier to deliver antigens. The discussion about their safe, effective, and affordable vaccines to immunize against COVID-19 will be highlighted. © Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antigen presenting cells (APCs); nanotechnology; vaccine

Year:  2021        PMID: 34659650      PMCID: PMC8501370          DOI: 10.1007/s12274-021-3832-y

Source DB:  PubMed          Journal:  Nano Res        ISSN: 1998-0000            Impact factor:   10.269


  427 in total

1.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Authors:  Gary P Kobinger; Heinz Feldmann; Yan Zhi; Gregory Schumer; Guangping Gao; Friederike Feldmann; Steven Jones; James M Wilson
Journal:  Virology       Date:  2005-12-13       Impact factor: 3.616

Review 2.  Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier.

Authors:  Mahmoud Gharbavi; Jafar Amani; Hamidreza Kheiri-Manjili; Hossein Danafar; Ali Sharafi
Journal:  Adv Pharmacol Sci       Date:  2018-12-11

3.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

4.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.

Authors:  Nicolas Escriou; Benoît Callendret; Valérie Lorin; Chantal Combredet; Philippe Marianneau; Michèle Février; Frédéric Tangy
Journal:  Virology       Date:  2014-01-28       Impact factor: 3.616

6.  Furin: A Potential Therapeutic Target for COVID-19.

Authors:  Canrong Wu; Mengzhu Zheng; Yueying Yang; Xiaoxia Gu; Kaiyin Yang; Mingxue Li; Yang Liu; Qingzhe Zhang; Peng Zhang; Yali Wang; Qiqi Wang; Yang Xu; Yirong Zhou; Yonghui Zhang; Lixia Chen; Hua Li
Journal:  iScience       Date:  2020-10-05

Review 7.  Particle size and pathogenicity in the respiratory tract.

Authors:  Richard James Thomas
Journal:  Virulence       Date:  2013-11-13       Impact factor: 5.882

8.  The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.

Authors:  Noton K Dutta; Kaushiki Mazumdar; James T Gordy
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

9.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

10.  A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.

Authors:  Zhimin Zhou; Penny Post; Rick Chubet; Katherine Holtz; Clifton McPherson; Martin Petric; Manon Cox
Journal:  Vaccine       Date:  2006-02-09       Impact factor: 3.641

View more
  3 in total

1.  Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.

Authors:  Diego Alejandro Dri; Elisa Gaucci; Ilaria Torrieri; Maria Carafa; Carlotta Marianecci; Donatella Gramaglia
Journal:  Pharmaceutics       Date:  2022-07-09       Impact factor: 6.525

2.  Amoeba-inspired magnetic microgel assembly assisted by engineered dextran-binding protein for vaccination against life-threatening systemic infection.

Authors:  Shuo Liu; Yan Zhao; Linpei Guo; Qilin Yu
Journal:  Nano Res       Date:  2022-09-02       Impact factor: 10.269

Review 3.  Localized delivery of nanomedicine and antibodies for combating COVID-19.

Authors:  Bin Tu; Yanrong Gao; Xinran An; Huiyuan Wang; Yongzhuo Huang
Journal:  Acta Pharm Sin B       Date:  2022-09-23       Impact factor: 14.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.